-
Personalized targeting of neoantigen autoimmune T cells in the treatment of multiple advanced solid tumors
Time of Update: 2022-04-27
cn At present, this treatment measure belongs to the clinical trial stage.
Patients with a history of severe immediate hypersensitivity to any drugs used in this study; 3.
-
Lilly's RET inhibitor shows long-term efficacy in the precise treatment of non-small cell lung cancer
Time of Update: 2022-04-27
▎WuXi AppTec Content Team Editor A few days ago, Eli Lilly and Company today announced updated data from a Phase 1/2 clinical trial of the RET inhibitor Retevmo (selpercatinib) in patients with RET fusion-positive non-small cell lung cancer (NSCLC) .
-
How will cancer change in China in 2022?
Time of Update: 2022-04-27
21 million deaths; the burden of liver, gastric and esophageal cancer in China will decrease, but lung, colorectal, breast and Increased burden on the prostate; advances in cancer prevention and care, as well as aggressive responses to population aging, may help reduce cancer burden in China .
-
Discovery of USP8 inhibition remodels the inflamed tumor microenvironment for enhanced immunotherapy
Time of Update: 2022-04-27
The deubiquitinase USP8 significantly enhances the efficacy of anti-PD-1/PD-L1 immunotherapy by remodeling the inflammatory tumor microenvironment (TME) .
This study reports that inhibition of the deubiquitinase USP8 significantly improves the efficacy of anti-PD-1/PD-L1 immunotherapy by remodeling the inflammatory tumor microenvironment (TME) .
-
Merck's c-Met inhibitor is declared for listing in China, Jiangsu Hansoh, Haihe Pharmaceutical are multi-enterprise layout, is there any chance for latecomers?
Time of Update: 2022-04-27
The marketing application of tepotinib hydrochloride was accepted, source: CDE official website Tepotinib (tepotinib, trade name Tepmetko) is an oral c-MET inhibitor that has been approved for marketing in Japan and the United States for the treatment of Non-small cell lung cancer (NSCLC) patients with MET exon 14 (MET ex14) skipping .
-
Leading the future: 3 major studies in perioperative treatment of NSCLC at a glance 2022 ELCC Voice of China
Time of Update: 2022-04-27
Osimertinib has shown satisfactory efficacy and acceptable safety in neoadjuvant therapy, and is a promising and potential treatment option for patients with resectable EGFR-mutant NSCLC .
This Phase Ib/III study evaluated the efficacy and safety of SHR-1316+chemotherapy versus placebo+chemotherapy for the perioperative treatment of resectable NSCLC .
-
[Nature Sub-Journal] Identify ways to limit the growth of metastatic cancer!
Time of Update: 2022-04-27
This study deciphers the role of cancer stem cell (CSCs)-regulated phenotypic plasticity in metastatic colonization and provides a therapeutic approach to limit metastatic growth .
DKK1 was identified as a key molecule that autonomously reduces the population of CSCs and subsequently promotes breast cancer metastatic colonization .
-
The target of liver cancer cell therapy from the world's first case of CAR-T cure for liver cancer (Part 1)
Time of Update: 2022-04-27
Considering other forms similar to CAR-T, such as CAR-NK, TCR-T, this article will review the targets of adoptive cell therapy for the treatment of liver cancer in two parts .
-
Express Doubled Progression-Free Survival, PARP Inhibitor First-Line Maintenance Therapy for Ovarian Cancer Phase 3 Clinical Results Positive
Time of Update: 2022-04-27
"Reference: [1] Clovis Oncology's Rubraca® (Rucaparib) Significantly Improves Progression-Free Survival in First-line Maintenance Treatment in Women with Ovarian Cancer Regardless of Their Biomarker Status in Phase 3 ATHENA-MONO Trial.
-
What should be done in colorectal cancer patients with MET amplification?
Time of Update: 2022-04-26
Fortunately, the patient underwent genetic testing in a timely manner under the condition of poor initial treatment effect, and it was confirmed that he received sevolitinib treatment in a timely manner after MET amplification, and finally achieved PR, and the subsequent tumor remission was further deepened .
-
Express uses artificial intelligence to develop oncology and NASH therapies, GlaxoSmithKline collaborates
Time of Update: 2022-04-26
▎WuXi AppTec Content Team Editor Today, PathAI and GlaxoSmithKline (GSK) jointly announced a multi-year strategic R&D collaboration that will leverage PathAI’s digital pathology technology platform (including its AIM-NASH tool) to accelerate oncology and Scientific research and drug development programs for nonalcoholic steatohepatitis (NASH) .
-
Case Sharing Hui Professor Lou Shifeng's Comments: Re-challenge after multi-drug refractory, the combination of Selinesol helps patients with plasma cell leukemia achieve complete remission
Time of Update: 2022-04-26
First-line treatment May 2020 Bortezomib combined with cyclophosphamide and dexamethasone (VCd) regimen, a total of 3 courses; the efficacy evaluation was complete remission (CR), bone marrow MRD was negative, immunofixation electrophoresis was negative, free light chain ratio Normal; extramedullary lesions shrink rapidly .
-
[Nature sub-issue] "Armed CAR-T cells" to better fight cancer and improve the possibility of successful treatment of solid tumors!
Time of Update: 2022-04-26
Recent studies have armed CAR-T cells to better fight cancer by introducing a gene encoding the immune-stimulating protein NAP (neutrophil-activating protein) from Helicobacter pylori, increasing the likelihood of successful treatment of solid tumors .
-
"The Lancet" Sub-Journal: Molecular typing can guide the selection of treatment options for renal cell carcinoma; FGFR inhibitor pemitinib is approved in China for the treatment of cholangiocarcinoma
Time of Update: 2022-04-26
*Only for medical professionals to read and reference for 1 minute a day, to give you professional "talks" in the tumor circle! (If you need the original text, you can add Xiaobian WeChat yxj_oncolog
-
ELCC 2022 Voice of China's domestic drugs shine!
Time of Update: 2022-04-26
Background The previous results of the ORIENT-11 study showed that compared with placebo + pemetrexed + platinum (PPP), the first-line treatment of sintilimab + pemetrexed + Platinum (SPP) significantly improves progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) .
-
The doctor of reinflammation will take you to fully understand the "clinical trial"
Time of Update: 2022-04-26
In the last episode of this issue, we continue to explore issues related to "clinical trials".
It is also hoped that more patients can benefit from different trials and ultimately overcome the diseases they face .
-
Satisfactory results of avelumab combined with SABR in the treatment of mCRPC
Time of Update: 2022-04-26
Table 2 Response resultsFigure 2 Antitumor activity and safety 28 patients (90%) experienced treatment-related adverse events (TRAEs), of which 5 were grade 3-4 TRAEs (16%), and 3 (10%) required high Dose cortisol therapy (without immunomodulators) and discontinue therapy .
-
100% Chinese population, better efficacy: ADAURA China subgroup analysis unveiled at 2022 ELCC
Time of Update: 2022-04-26
Introduction In the ADAURA global clinical study, adjuvant osimertinib in the treatment of stage II-IIIA EGFR mutation-positive NSCLC brought an overwhelming DFS benefit, reducing the risk by 83% (HR 0.
-
Advances in Exploration: Overcoming Obstacles to the Application of Cell Delivery Systems in Tumor Immunotherapy
Time of Update: 2022-04-26
Recently, Exploration published the latest review "Recent Advances in Overcoming Barriers to Cell-based Delivery Systems for Cancer Immunotherapy" by Professor Hu Quanyin's team .
-
Professor Gu Yanhong: Multi-line chemotherapy for colorectal cancer failed, but immunotherapy achieved tumor remission and helped chronic disease management
Time of Update: 2022-04-26
Based on the results of its Phase II registration study, Nvolizumab was approved by the National Medical Products Administration (NMPA) of China on November 25 for the treatment of adult patients with advanced solid tumors with MSI-H/dMMR .
